Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma

Biomarkers in Medicine

Volumn 9, Issue 9, 2015, Pages 901-910

  Warf, M Bryan ^a   Fosso, Placede G ^a   Hughes, Elisha ^a   Perry, Michael ^a   Brown, Krystal L ^a   Reid, Julia E ^a   Kolquist, Kathryn A ^a   Wagner, Susanne ^a   Gutin, Alexander ^a   Roa, Benjamin ^a  

^a Utah   (United States)

Author keywords

analytical validation; cell cycle progression; early stage lung adenocarcinoma; FFPE; gene expression; quantitative RT PCR

Indexed keywords

PARAFFIN; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL CYCLE PROGRESSION; CONTROLLED STUDY; EARLY CANCER; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; HOUSEKEEPING GENE; LUNG ADENOCARCINOMA; LUNG RESECTION; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA STABILITY; VALIDATION STUDY; ADENOCARCINOMA; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL; TUMOR GENE;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; LINEAR MODELS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RNA STABILITY;

EID: 84942853266     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.46     Document Type: Article

References (20)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9-29 (2014).
2. Chansky K, Sculier JP, Crowley JJ et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J. Thorac. Oncol. 4(7), 792-801 (2009).
3. Tsuboi M, Ohira T, Saji H et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann. Thorac. Cardiovasc. Surg. 13(2), 73-77 (2007).
4. Crino L, Weder W, Van Meerbeeck J, Felip E, Group EGW. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v103-v115 (2010).
5. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26(21), 3552-3559 (2008).
6. Pisters KM, Evans WK, Azzoli CG et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J. Clin. Oncol. 25(34), 5506-5518 (2007).
7. Strauss GM, Herndon JE, 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J. Clin. Oncol. 26(31), 5043-5051 (2008).
8. Subramanian J, Simon R. Overfitting in prediction models-is it a problem only in high dimensions Contemp. Clin. Trials 36(2), 636-641 (2013).
9. Bueno R, Hughes E, Wagner S et al. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J. Thorac. Oncol. 10(1), 67-73 (2015).
10. Wistuba Ii, Behrens C, Lombardi F et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin. Cancer Res. 19(22), 6261-6271 (2013).
11. Whitfield ML, Sherlock G, Saldanha AJ et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell. 13(6), 1977-2000 (2002).
12. Cuzick J, Swanson GP, Fisher G et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 12(3), 245-255 (2011).
13. Clark-Langone KM, Sangli C, Krishnakumar J, Watson D. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX(® )Colon Cancer Assay. BMC Cancer 10, 691-691 (2010).
14. Nielsen T, Wallden B, Schaper C et al. Analytical validation of the PAM50-based prosigna breast cancer prognostic gene signature assay and nCounter analysis system using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 14, 177 (2014).
15. Warf MB, Flake DD 2nd, Adams D et al. Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions. Biomark. Med. 9(5), 407-416 (2015).
16. Radstrom P, Knutsson R, Wolffs P, Lovenklev M, Lofstrom C. Pre-PCR processing: strategies to generate PCR-compatible samples. Mol. Biotechnol. 26(2), 133-146 (2004).
17. Wilson IG. Inhibition and facilitation of nucleic acid amplification. Appl. Environ. Microbiol. 63(10), 3741-3751 (1997).
18. Dorrie J, Wellner V, Kampgen E, Schuler G, Schaft N. An improved method for RNA isolation and removal of melanin contamination from melanoma tissue: implications for tumor antigen detection and amplification. J. Immunol. Methods 313(1-2), 119-128 (2006).
19. Mirsadraee M, Shafahie A, Reza Khakzad M, Sankian M. Value of the polymerase chain reaction method for detecting tuberculosis in the bronchial tissue involved by anthracosis. J. Bronchology Interv. Pulmonol. 21(2), 131-134 (2014).
20. Wang D, Wang J, Li Y, He Z, Zhang Y. The influence of anthracosis and p16 ink4a gene aberrant methylation on small-sized pulmonary adenocarcinoma. Exp. Mol. Pathol. 90(1), 131-136 (2011).